Glycoengineering of AAV-delivered monoclonal antibodies yields increased ADCC activity.
Saved in:
| Title: | Glycoengineering of AAV-delivered monoclonal antibodies yields increased ADCC activity. |
|---|---|
| Authors: | Termini JM; Department of Pathology, University of Miami Miller School of Medicine, Miami, FL, USA., Martinez-Navio JM; Department of Pathology, University of Miami Miller School of Medicine, Miami, FL, USA., Gao G; Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, USA., Fuchs SP; Department of Pathology, University of Miami Miller School of Medicine, Miami, FL, USA., Desrosiers RC; Department of Pathology, University of Miami Miller School of Medicine, Miami, FL, USA. |
| Source: | Molecular therapy. Methods & clinical development [Mol Ther Methods Clin Dev] 2020 Nov 11; Vol. 20, pp. 204-217. Date of Electronic Publication: 2020 Nov 11 (Print Publication: 2021). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Cell Press Country of Publication: United States NLM ID: 101624857 Publication Model: eCollection Cited Medium: Print ISSN: 2329-0501 (Print) Linking ISSN: 23290501 NLM ISO Abbreviation: Mol Ther Methods Clin Dev Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
